Purpose. Appendiceal mucinous neoplasms (AMN) are a rare heterogeneous group of diseases. In the absence of randomized trials, AMN management is controversial. The goal of this study was to evaluate the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery on survival in AMN patients. Patients and Methods. Patient data including demographics, pathology, type of therapy, and outcomes were collected from Emory University, the Ohio State University, and Wayne State University databases. One of the three centers did not use HIPEC. Statistical analysis evaluating overall survival (OS) of AMN patients was performed. Results. Between 1990 and 2010, 163 AMN patients were identified. Histology showed 60 patients had diffuse peritoneal adenomucinosis, 88 had peritoneal mucinous carcinomatosis (PMCA), and 15 had PMCA with indeterminate or discordant features. Complete surgical resection was achieved in 76 patients. HIPEC was used in 79 patients. The median OS was 77 months for patients who received HIPEC compared with 25 months for patients who did not (p , .001). In multivariable analysis, histopathologic subtype (p , .001), complete surgical resection (p , .001), and HIPEC (p , .001) were independent predictors for improved OS. A survival advantage for AMN patients treated at HIPEC-treating centers was observed (p 5 .0026). After adjusting for HIPEC therapy, no significant survival difference was observed between the non-HIPEC-treating center and the HIPEC-treating centers (p 5 .094).
INTRODUCTION
Epithelial neoplasms of the appendix are rare tumors with an age-adjusted incidence of 0.12 case per 1 million persons per year [1] . Appendiceal mucinous neoplasms (AMNs) are a heterogeneous group of diseases with varying degrees of pathologic differentiation [2] [3] [4] . The clinical course of AMN patients is determined by the pathologic degree of differentiation and the stage of the disease at diagnosis [5, 6] . More than 50% of AMN patients present with diffuse mucinous ascites, a condition referred to as "pseudomyxoma peritonei" (PMP). Patients who present with PMP have a worse prognosis than patients presenting with localized tumors and no extra-appendiceal spread [5, 7] .
The classification system used in our institutions is the Ronnett classification [8] . This system classifies AMN into three major histologic subtypes: disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), and PMCA with indeterminate or discordant features (PMCA I/D). The Ronnett classification is focused on the pathologic features of the PMP.The three histologic subtypes represent a spectrum of clinical behavior ranging from the least aggressive (DPAM) to the most aggressive (PMCA) histology [8] . Metastasis associated with DPAM is usually limited to the peritoneal cavity and does not involve lymph nodes or extra-abdominal sites. PMCA, however, can involve lymph node, peritoneal, and extra-abdominal metastasis [9] . In a retrospective chart review of 40 AMN patients, the median survival of patients with DPAM, PMCA I/D, and PMCA was 7.7 years, 1.2 years, and 0.7 year, respectively [9] , suggesting that pathological differentiation is a very important predictor of survival [10] . Given the rarity of AMN and the complexity of the pathologic classification, treatment options depend on retrospective trials and include debulking surgery and intraperitoneal and systemic chemotherapy. Although surgery is an accepted treatment for all stages of the disease, the role of intraperitoneal and systemic chemotherapy for AMN remains unclear [11] . Analyses from patient series evaluating the use of chemotherapy prior to debulking surgery or hyperthermic intraperitoneal chemotherapy (HIPEC) during surgery have shown conflicting results [12, 13] . Limitations of the published series include singleinstitutional biases, the retrospective nature of the trials, and lack of statistical power [12] [13] [14] . In addition, HIPEC is used only in patients who have complete surgical resection in many centers. Complete surgical resection is associated with improved survival [14] [15] [16] [17] . Consequently, retrospective studies that evaluated the impact of HIPEC had a selection bias because HIPEC is not administered to patients with gross residual disease after cytoreduction. Given the controversial role of HIPEC in the management of AMN, we evaluated the experience of patients treated with surgery alone or with surgery plus HIPEC in three tertiary care centers, one of which does not use HIPEC treatment as a modality in managing AMN patients.
PATIENTS AND METHODS

Patient Selection and Data Collection
The institutional review boards at the respective centersthe Winship Cancer Institute at Emory University, the Arthur James Cancer Center at the Ohio State University, and the Karmanos Center at Wayne State University-approved the conduct of the study. Eligibility criteria included newly diagnosed, previously untreated patients with DPAM, PMCA, or PMCA I/D histology [6] and peritoneal metastasis who were treated at any of the three institutions between July 1990 and July 2010. Patients were identified by each institution's tumor registry. Exclusion criteria included appendiceal tumors with nonmucinous histology (neuroendocrine, goblet cell carcinoid, signet ring cell cancer, or appendiceal cystadenomas) and absence of peritoneal metastasis. In addition, patients were excluded if they were previously treated in an outside institution or if they were seen only once for a second opinion. Data collected included age, sex, pathology, type of treatment (systemic chemotherapy, type of surgery, and HIPEC), extent of cytoreductive surgery (complete or incomplete), peritoneal cancer index, and survival. Pathologic parameters collected included histological grade, histopathologic subtype (DPAM, PMCA, or PMCA I/D), and stage. HIPEC was used in two of the three centers. All patients were managed by a multidisciplinary team with a small number of experienced surgeons at each institution. HIPEC was administered at the completion of cytoreductive surgery using an open technique, with the pump circuit and the chemoperfusate heated to achieve a temperature of 40°C. HIPEC with 30 mg mitomycin C was delivered over a 60-minute period with abdominal irrigation. After the 60-minute period, another 10 mg mitomycin C was infused over a 30-minute period.The patient's core body temperature was kept under 38.5°C. The HIPEC protocol used was the same in the two HIPEC-treating centers. Complete surgical resection was defined as absence of any disease .2.5 mm following resection, as assessed by the operating surgeon.Incomplete surgical resectionwas defined as persistent disease of $2.5 mm following resection.
The peritoneal cancer index (PCI) is used to assess the distribution of the disease involving the regions of the peritoneal surface. The abdominal surface is divided into 13 regions. A lesion size score (LSS) is determined in each region (score is 0, 1, 2, or 3, according to size of the lesion). The summation of the LSS in each of the 13 abdominopelvic regions is the PCI. This score is determined intraoperatively and is calculated to be 0-3 in each of the 13 abdominopelvic regions, for a computed PCI score of 0-39 [18] .
Statistical Analysis
Patient survival data were obtained from the US Social Security Death Index. The survival time was calculated in months from the date of cytoreductive surgery to death or last follow-up. Survival rates for variables of interest were estimated by the Kaplan-Meier method and compared with the log-rank test [19] . A Cox proportional hazards model was further fitted to estimate the adjusted effect of variables on OS. Univariate survival analysis for centers using HIPEC compared with the center that does not use HIPEC as part of the treatment modality was carried out using the Cox proportional hazards model [20] . The proportional hazards assumption was checked. The multivariable survival analysis of HIPEC-treating centers compared with the non-HIPECtreating center was further conducted with a Cox proportional hazards model after adjusting for HIPEC. Backward selection with an a level of removal of.1 was used.The following variables were removed from the multivariate model: age, race, sex, treatment, and year of diagnosis. The SAS statistical package version 9.3 (SAS Institute, Inc., Cary, NC, http://www.sas.com) was used for data analyses with a significance level of.05.The OS was censored at 60 months (5 years). The median follow-up time was 53.1 months (95% confidence interval [CI]: 40.69-60).
RESULTS
Patient Characteristics
Based on the eligibility criteria, 163 patients were identified. Patient characteristics are presented in Table 1 . The median age at diagnosis was 52 years (range: 29-67 years). DPAM, ©AlphaMed Press 2015
The Oncologist ® PMCA, and PMCA I/D histologies were present in 60 (36.8%), 88 (54%), and 15 (9.2%) patients, respectively. All patients had PMPat presentation.Whentheyearsofdiagnosisweredividedinto5-year intervals, more patients were treated at our centers over time.
Patient characteristics were compared for patients treated at centers that used HIPEC and for those treated at the center that did not use HIPEC ( Table 2) . A statistically significant difference in racial distribution was observed between the HIPEC-treating centers (white 83.8%) and the non-HIPEC center (white 44.4%) (p 5 .001). More than half (58.1%) of the patients treated at the HIPEC-treating centers received HIPEC.
Treatment
Overall, 118 patients (72.4%) received surgery. Of those patients, 76 (64%) had complete surgical resection and 42 (36%) had incomplete resection. In the HIPEC-treating centers, 99 patients (73%) had surgery, 65 of whom (65%) had compete resection. Of the 65 patients who had complete surgical resection, 48 (73.8%) received HIPEC. The median PCI of the treated patients was 17.2 (range: 3-39). The median PCI for patients receiving HIPEC was 6.8 (range: 3-26), and median PCI for those who did not receive HIPEC was 29.8 (range: 12-39). The median PCI for patients treated at the non-HIPEC-treating center was 18.1 (range: 9-33) compared with 16.4 (range: 3-39) for those treated at the HIPEC-treating centers. PCI data were available for only 82 patients. In the non-HIPEC-treating center, 19 patients (70%) had surgery and 11 (58%) achieved complete resection. 
Survival Outcomes
The median OS for all patients in the series was 55 months. The OS was influenced by histology, HIPEC, systemic (Fig. 3) . Patients who underwent complete surgical resection had significantly better OS compared with patients who had incomplete resection (p 5 .045) (Fig. 4 ). The median OS was significantly higher in patients who had complete surgical resection (not reached yet) compared with patients with incomplete resection (21.9 months) (HR: 0.21; 95% CI: 0.11-0.41; p , .001). In multivariate analysis, HIPEC and complete surgical resection remained significant predictors of OS (HR: 0.14; 95% CI: 0.07-0.28; p , .001). After adjusting for HIPEC treatment, there was no significant difference in OS between patients treated at HIPEC-treating centers compared with the non-HIPEC-treating center (p 5 .094). There was a significant survival difference over time (p , .001) when the year of diagnosis was stratified into 5-year intervals; however, this did not hold true when stratified into 10-year intervals (p 5 .22)
DISCUSSION
The impact of histology and treatment modality on survival for patients with AMN is clearly demonstrated in our series. The Ronnett classification [6] is used because it was the approved classification system at the time of patient evaluation in the three study institutions. Furthermore, the prognoses for the three histologies classified in the Ronnett classification system overlap the prognosis defined by the grade of the disease [21] . Patients with PMCA histology had significantly shorter survival than DPAM. These observations are consistent with other published series [6, 8, 14] and highlight the need to consider histology and grade of the tumor to properly prognosticate and manage patients with AMN. Cytoreductive surgery remains the cornerstone of therapy in AMN [22, 23] . Spratt et al. introduced the addition of HIPEC to cytoreductive surgery for the treatment of AMN in 1980 [24] . Several case series confirmed the benefits related to cytoreductive surgery combined with HIPEC [12, [25] [26] [27] . In our series, complete surgical resection was shown to be a significant independent predictor of survival. This observation is in agreement with previously published literature. In the largest series with 2,298 patients, complete surgical resection was shown to be the strongest independent factor for OS in AMN patients. Patients with high PCI scores were less likely to achieve complete cytoreduction. To account for this, a comparison between HIPEC and non-HIPEC treatment was evaluated; in addition, comparison between HIPECtreating centers and a non-HIPEC-treating center was done. The addition of intraperitoneal therapy to the cytoreductive surgery showed statistically significant improved progressionfree survival but did not show OS benefit. Of note, as reported by Chua et al., only 9% of patients did not receive any intraperitoneal therapy. In addition, intraperitoneal chemotherapy is not standardized in their multi-institutional report, as 60% of patients received HIPEC, 29% received both early postoperative intraperitoneal chemotherapy (EPIC) and HIPEC, and 2% received EPIC. Furthermore, 11% of the HIPEC group received oxaliplatin as part of HIPEC, whereas 77% received mitomycin C [14] . In our series, approximately half of the patients received HIPEC as part of their treatment, and the HIPEC protocol was the same at the two HIPEC-treating centers. The fact that one of our centers did not use HIPEC as part of its standard treatment for AMN suggests that the difference in outcomes is less likely to be due to selection bias. The Oncologist ® Furthermore, 26.2% of patients who achieved complete cytoreduction did not receive HIPEC in the HIPEC-treating centers because of hemodynamic instability of the patients and length of the surgery. A statistically significant survival advantage favoring the use of HIPEC following surgical resection was observed. The benefit from HIPEC treatment persisted even after adjusting for treatment center (HIPECtreating centers vs. non-HIPEC-treating center) and extent of surgical resection (complete vs. incomplete), further confirming the beneficial role of HIPEC in the management of AMN. The trend of time is a potential bias because better surgical techniques and use of HIPEC were defined over the period of this study. There was a statistically significant difference in survival if the time periods were classified at 5year intervals. This could also be related to earlier diagnosis with better imaging modalities or use of HIPEC. Although systemic chemotherapy is an option for patients who are nonsurgical candidates [11, 28] , its role in resectable disease and medically fit patients is controversial. In a study by Bijelic et al. [29] , neoadjuvant systemic 5-fluorouracil-based chemotherapy in patients with PMCA resulted in complete or near-complete histologic response, translating to smaller surgical resections. In contrast, administration of systemic chemotherapy has been shown to be an adverse predictor of survival in AMN patients undergoing debulking surgery and HIPEC [28] . In our series, patients who did not receive systemic chemotherapy had significant improvement in OS compared with those who received chemotherapy. Possible reasons contributing to the poor outcome of patients who received systemic chemotherapy could include more aggressive histology, selection of patients with higher disease burden, selection of patients with incomplete debulking surgery, side effects of chemotherapy, or delay of surgery. Given the currently available data, routine use of pre-or postoperative chemotherapy in patients with disease confined to the appendix or peritoneal spread with DPAM histology cannot be recommended. The use of preoperative chemotherapy in patients with peritoneal spread from PMCA remains controversial [11, [29] [30] [31] .
CONCLUSION
Our series confirms that histopathology, systemic chemotherapy, complete surgical resection, and HIPEC are significant predictors of OS. In our study, complete surgical resection followed by HIPEC was found to be the most effective therapeutic option. The challenge of conducting prospective trials in this rare disease mandates cooperation at national and international levels to develop therapeutic protocols that can define pathologic classification and treatment strategies. 
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